| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
11,450,000 |
| Market
Cap: |
8.59(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.2893 - $1.35 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Monopar Therapeutics is a biopharmaceutical company focused on developing proprietary therapeutics for cancer patients. Co.'s compounds in development: Validive®, a Phase 2b/3 clinical stage, mucoadhesive buccal tablet for the prevention of radiation induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin, a Phase 1b clinical stage analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart; MNPR-101, a preclinical stage uPAR-targeted antibody being developed as a radioimmunotherapeutic and companion diagnostic for cancers and COVID-19; and an early stage camsirubicin analog, MNPR-202, for various cancers.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
16,053 |
| Total Buy Value |
$0 |
$0 |
$0 |
$49,659 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Starr Christopher M |
|
– • – |
2022-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,859 |
10,012 |
|
- |
|
| Tsuchimoto Kim R |
Chief Financial Officer |
• – – |
2022-03-31 |
4 |
D |
$2.55 |
$1,275 |
D/D |
(500) |
5,636 |
|
- |
|
| Tsuchimoto Kim R |
Chief Financial Officer |
• – – |
2022-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,221 |
6,136 |
|
- |
|
| Mazar Andrew Paul |
Chief Scientific Officer |
• • – |
2022-03-31 |
4 |
D |
$2.55 |
$1,201 |
D/D |
(471) |
22,125 |
|
- |
|
| Mazar Andrew Paul |
Chief Scientific Officer |
• • – |
2022-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,606 |
22,596 |
|
- |
|
| Anderson Raymond |
|
– • – |
2022-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,859 |
8,153 |
|
- |
|
| Robinson Chandler |
Chief Executive Officer |
• • – |
2022-03-31 |
4 |
D |
$2.55 |
$2,945 |
D/D |
(1,155) |
36,519 |
|
- |
|
| Robinson Chandler |
Chief Executive Officer |
• • – |
2022-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,941 |
37,674 |
|
- |
|
| Starr Christopher M |
|
– • – |
2022-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,859 |
7,153 |
|
- |
|
| Klausner Arthur J |
|
– • – |
2022-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,859 |
12,153 |
|
- |
|
| Brown Michael J |
|
– • – |
2022-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,859 |
217,153 |
|
- |
|
| Tsuchimoto Kim R |
Chief Financial Officer |
• – – |
2022-01-01 |
4 |
D |
$3.21 |
$1,621 |
D/D |
(505) |
4,915 |
|
- |
|
| Tsuchimoto Kim R |
Chief Financial Officer |
• – – |
2022-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,231 |
5,420 |
|
- |
|
| Mazar Andrew Paul |
Chief Scientific Officer |
• • – |
2022-01-01 |
4 |
D |
$3.21 |
$2,154 |
D/D |
(671) |
20,990 |
|
- |
|
| Mazar Andrew Paul |
Chief Scientific Officer |
• • – |
2022-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,937 |
21,661 |
|
- |
|
| Robinson Chandler |
Chief Executive Officer |
• • – |
2022-01-01 |
4 |
D |
$3.21 |
$7,470 |
D/D |
(2,327) |
33,733 |
|
- |
|
| Robinson Chandler |
Chief Executive Officer |
• • – |
2022-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,724 |
36,060 |
|
- |
|
| Anderson Raymond |
|
– • – |
2021-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
751 |
5,294 |
|
- |
|
| Tsuchimoto Kim R |
Chief Financial Officer |
• – – |
2021-12-31 |
4 |
D |
$3.21 |
$1,608 |
D/D |
(501) |
4,189 |
|
- |
|
| Tsuchimoto Kim R |
Chief Financial Officer |
• – – |
2021-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,221 |
4,690 |
|
- |
|
| Robinson Chandler |
Chief Executive Officer |
• • – |
2021-12-31 |
4 |
D |
$3.21 |
$4,378 |
D/D |
(1,364) |
29,336 |
|
- |
|
| Robinson Chandler |
Chief Executive Officer |
• • – |
2021-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,941 |
30,700 |
|
- |
|
| Starr Christopher M |
|
– • – |
2021-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
751 |
4,294 |
|
- |
|
| Klausner Arthur J |
|
– • – |
2021-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
751 |
9,294 |
|
- |
|
| Brown Michael J |
|
– • – |
2021-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
751 |
214,294 |
|
- |
|
155 Records found
|
|
Page 4 of 7 |
|
|
0.01 (1.57%) 
